Desde 500€ puedes invertir en Biocross a través de Blockchain
the life expectancy and quality of life of individuals with neurodegenerative diseases
through the design of innovative diagnostic systems.
and non-invasive diagnostic tools that can be used
at any stage of the disease.
Early diagnosis
Reliable
Non-invasive
Our goal
To provide neurologists with an integrated diagnostic solution that can be applied to any stage of the disease, including the earliest, asymptomatic phase.
Benefits
- Reduced cost of AD risk-assessment and diagnosis.
- More widespread testing thanks to simpler, more readily available diagnostic methods.
- Improved diagnosis, through earlier detection and differentiation of distinct dementia types.
- Simplified diagnosis through leveraging of existing laboratory equipment.
- Improved patient experience and safety.
The e4Risk® is a non-genetic, cost-effective, and highly reliable method to detect the presence of the ApoE4 protein in human blood plasma using high-throughput chemical analysis.
The AD Dementia test is a multiparametric test that combines the detection and quantification of up to 9 metabolites or proteins in a plasma sample. The input of these measurements into an algorithm provides an accurate diagnosis and classifies the patient as either Alzheimer´s disease or frontotemporal dementia.
The Degenerative dementia test is based on the detection and quantification of up to 7 blood biomarkers that are specifically altered in patients affected by neurodegeneration due to FTD or AD. The DD test is conceived as a “screening” tool for use in clinical practice.
El CREA participa en una investigación para evaluar un nuevo método de cribado de alzhéimer
La empresa Biocross ha proyectado un estudio para evaluar la cuantificación de la Apolipoproteína E4 (ApoE4) como marcador de riesgo de padecer alzhéimer, enfermedades cardiovasculares y diabetes mellitus tipo II. En este proyecto, en la que colaboran diversas...
DIÁLOGOS CERCO AL ALZHEIMER
¿Cuál es el coste social del Alzheimer? ¿Hasta dónde puede y debe llegar la Atención Primaria en el diagnóstico de los enfermos? ¿Cómo garantizar un acceso igualitario de los pacientes a las mejores terapias integrales? El momento de hacer preguntas como estas es...
Apoe4: Descubierta una nueva causa genética del alzhéimer que afecta a más del 2% de la población
10/05/2024 El Instituto de Investigación del Hospital de la Santa Creu i Sant Pau de Barcelona ha identificado una nueva causa genética del Alzheimer: la duplicidad del gen APOE4. Este descubrimiento resalta la importancia del gen APOE4 en la investigación del...
If you have any questions or comments, we will be pleased to attend you
Avda. Francisco Vallés, 8
47151 Boecillo (Valladolid) - Spain
+34 983 54 98 96
